[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM: Nipple aspirate fluid cytology in breast carcinoma. Cancer; 2003 Apr 25;99(2):97-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate fluid cytology in breast carcinoma.
  • BACKGROUND: Nipple aspirate fluid (NAF) cytology is a simple noninvasive method to study cells exfoliated into the ductal system of the breast.
  • In the current study, the significance of cytologic findings in NAF was determined by correlating them with histopathologic findings from corresponding breast tissue.
  • METHODS: Nipple aspirate fluid was collected by breast massaging and by using a breast aspiration device from 74 women with biopsy confirmed intraductal or invasive carcinoma with or without a history of preoperative neoadjuvant chemotherapy.
  • Finally, they were correlated with tissue findings.
  • RESULTS: Nipple aspirate fluid was obtained from 74 women, including 24 who had received preoperative neoadjuvant chemotherapy.
  • Patients treated with chemotherapy had fewer epithelial cells in their NAF compared with patients who were not treated with chemotherapy.
  • Of the five cases with mildly atypical cytology, three were intraductal papilloma, one was low-grade papillary intraductal carcinoma, and one was low-grade intracystic papillary carcinoma with invasion in the corresponding tissue specimen.
  • The single case with markedly atypical NAF cytology had extensive ductal carcinoma in situ (DCIS).
  • Of the four cases with malignant NAF cytology, two were extensive DCIS and two had invasive carcinoma with extensive DCIS in the breast specimen.
  • Nipple aspirate fluid is not a sensitive test for detecting invasive carcinoma of the breast.
  • Atypical cytology in NAF is associated with papillary lesions in the underlying breast.
  • [MeSH-major] Breast / cytology. Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Nipples

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12704689.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Lee Ch K, Schwartz J R, Iglesis G R, Vélez F R, Gómez S L: [Occult breast cancer: Report of two cases]. Rev Med Chil; 2006 Sep;134(9):1166-70
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occult breast cancer: Report of two cases].
  • Occult breast cancer is expressed as a metastatic axillary lymph node without clinical or imaging evidence of a primary tumor in the breast.
  • Its incidence is low, representing only 0.3 to 1% of all breast cancer cases.
  • The treatment of isolated axillary metastases of breast cancer is controversial.
  • However, in patients without radiological lesions in the breast, the tendency is not to perform a radical mastectomy as previously recommended, since the primary tumor will not be found in the surgical specimen in two thirds of cases.
  • An expecting behavior is not recommended as a therapeutic alternative.
  • Treatment should be complemented with hormonal therapy or chemotherapy.
  • We report two patients with a well defined occult breast cancer and based on them, a review of the subject is attempted.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Papillary / secondary. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Aged. Axilla. Biopsy. Breast / pathology. Combined Modality Therapy / methods. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Magnetic Resonance Imaging. Mammography. Mastectomy, Segmental. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171219.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


3. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK: Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev; 2007 Jul;16(7):1400-7
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study.
  • BACKGROUND: Few epidemiologic studies have examined the association between fertility drugs and breast cancer risk, and results have been contradicting.
  • Using data from the largest cohort of infertile women to date, the aim of this study was to examine the effects of fertility drugs on breast cancer risk overall and according to histologic subtypes.
  • A detailed data collection, including information of type and amount of treatment, was conducted.
  • We used case-cohort techniques to calculate rate ratios (RR) of breast cancer associated with use of five groups of fertility drugs, after adjustment for parity status.
  • RESULTS: Three hundred thirty-one invasive breast cancers were identified in the cohort during follow-up through 1998.
  • Analyses within cohort showed no overall increased breast cancer risk after use of gonadotrophins, clomiphene, human chorionic gonadotrophin, or gonadotrophin-releasing hormone, whereas use of progesterone increased breast cancer risk (RR, 3.36; 95% confidence interval, 1.3-8.6).
  • For all groups of fertility drugs, no relationships with number of cycles of use or years since first use of fertility drug were found.
  • However, gonadotrophins may have a stronger effect on breast cancer risk among nulliparous women (RR, 1.69; 95% confidence interval, 1.03-2.77).
  • Similar risk patterns were present for ductal, lobular, and tumors of other histologies, indicating identical etiologies.
  • CONCLUSION: The results showed no strong association between breast cancer risk and use of fertility drugs.
  • Follow-up is, however, needed to assess long-term breast cancer risk after use of progesterone and among nulliparous women exposed to gonadotrophins.
  • [MeSH-major] Breast Neoplasms / epidemiology. Fertility Agents, Female / administration & dosage. Infertility, Female / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adolescent. Adult. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / epidemiology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Case-Control Studies. Cohort Studies. Denmark / epidemiology. Female. Humans. Incidence. Middle Aged. Population Surveillance. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585058.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fertility Agents, Female
  •  go-up   go-down


Advertisement
4. Fayanju OM, Ritter J, Gillanders WE, Eberlein TJ, Dietz JR, Aft R, Margenthaler JA: Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy. Am J Surg; 2007 Oct;194(4):497-500
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy.
  • BACKGROUND: The role of radiation and endocrine therapy in the treatment of intracystic papillary carcinoma (IPC) remains unclear.
  • The aim of the current study was to review the management of IPC in order to determine factors associated with use of adjuvant therapies.
  • These patients were further divided into those with pure IPC (n = 21), IPC with associated ductal carcinoma in situ (DCIS) (n = 18), and IPC with associated microinvasion with or without DCIS (n = 6).
  • RESULTS: Patients with IPC and microinvasion were more likely to undergo an axillary staging procedure (6/6, 100%) compared to patients with pure IPC (6/21, 29%) or IPC with DCIS (5/18, 28%) (P < .001).
  • Patients with pure IPC were less likely to have radiation therapy than patients with IPC and DCIS or microinvasion (P < .001).
  • However, within the subset of patients with pure IPC, women less than 50 years of age were more likely to have radiation therapy than those older than 50 years (P < .001).
  • Patients with IPC and DCIS or microinvasion had significantly increased use of endocrine therapy versus patients with pure IPC (P < .01).
  • CONCLUSIONS: In our patient population, those patients with IPC and associated DCIS or microinvasion are treated with adjuvant radiation and endocrine therapy on the basis of this associated pathology.
  • The use of adjuvant radiation and/or endocrine therapy should be considered in patients with pure IPC who are of young age (<50 years).
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826064.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


5. Rachid S, Yacouba H, Hassane N: Male breast cancer: 22 case reports at the National Hospital of Niamey-Niger (West Africa). Pan Afr Med J; 2009;3:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer: 22 case reports at the National Hospital of Niamey-Niger (West Africa).
  • BACKGROUND: Male breast cancer (MBC) is rare.
  • The objective of the study is to report clinicopathological characteristics, treatment patterns, and outcomes of MBC.
  • METHOD: This study, which includes two parts (retrospective and prospective), focused on all hospitalized male patients with breast cancer during 17 years (1992-2008) with histological confirmation.
  • MBC represented 5.7% of all breast cancers.
  • Histology found infiltrating ductal carcinoma in 14 cases (63.6%), sarcoma in 3 cases (13.6%), papillary carcinoma in 2 cases (9%), and lobular carcinoma, medullar carcinoma, and mucinous carcinoma in 4.6% each of the others cases.
  • The treatment had consisted of a radical mastectomy (Halsted or Patey) in 19 cases (86.4%) with axillary clearance and incomplete resection in 3 cases (13.6%).
  • The absence of radiotherapy and the low access of chemotherapy limited the treatment to radical mastectomy (Halsted) in the majority of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Niger Postgrad Med J. 2009 Jun;16(2):166-70 [19606200.001]
  • [Cites] Bull Cancer. 2005 Mar;92(3):281-5 [15820923.001]
  • [Cites] West Afr J Med. 2005 Jan-Mar;24(1):36-40 [15909708.001]
  • [Cites] Yonsei Med J. 2008 Dec 31;49(6):978-86 [19108022.001]
  • [Cites] Mali Med. 2006;21(3):43-9 [19435008.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):629-39 [10091736.001]
  • [Cites] Bull Cancer. 1999 Mar;86(3):302-6 [10210765.001]
  • [Cites] Ann Intern Med. 2002 Oct 15;137(8):678-87 [12379069.001]
  • [Cites] Ann Chir. 2002 Oct;127(8):619-23 [12491637.001]
  • [Cites] Breast Cancer Res Treat. 1992;21(1):55-62 [1391975.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6 [15668471.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1471-7 [17342768.001]
  • [Cites] Ann Surg. 1978 Jul;188(1):60-5 [208472.001]
  • [Cites] Surg Clin North Am. 1990 Oct;70(5):1165-77 [2218826.001]
  • [Cites] Br J Cancer. 1985 Jul;52(1):99-103 [4015955.001]
  • [Cites] J Chir (Paris). 1995 Mar;132(3):131-6 [7782385.001]
  • [Cites] Bull Cancer. 1997 Feb;84(2):175-7 [9180841.001]
  • (PMID = 21532724.001).
  • [ISSN] 1937-8688
  • [Journal-full-title] The Pan African medical journal
  • [ISO-abbreviation] Pan Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC2984291
  • [Keywords] NOTNLM ; Male breast cancer / Niger / treatment
  •  go-up   go-down


6. Kurosumi M, Tabei T, Inoue K, Takei H, Ninomiya J, Naganuma R, Suemasu K, Higashi Y, Tsuchiya E: Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients. Oncol Rep; 2003 Jul-Aug;10(4):833-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients.
  • This study aimed to determine the prognostic significance of histological scoring system based on heterogeneity of invasive ductal carcinoma, for node-negative breast cancer patients.
  • We studied 108 patients of node-negative invasive ductal carcinoma with invasive tumor >5 mm.
  • Histological score of each patient was evaluated based on histological subtype of invasive ductal carcinoma and pattern of its heterogeneity.
  • Score of each subtype was defined as follows; papillotubular carcinoma: score 1, solid-tubular carcinoma: score 2 and scirrhous carcinoma: score 3.
  • These results suggested that assessment of histological heterogeneity of invasive ductal carcinoma could serve as independent potent prognostic factor for node-negative invasive ductal carcinoma of the breast, and this method might be useful to decide indication of postoperative adjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Papillary / classification. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Scirrhous / classification. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Lymph Nodes / metabolism. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792731.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


7. Yoney A, Kucuk A, Alan O, Unsal M: A retrospective study of treatment and outcome in 39 cases of male breast cancer. Hematol Oncol Stem Cell Ther; 2008 Apr-Jun;1(2):98-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of treatment and outcome in 39 cases of male breast cancer.
  • BACKGROUND AND OBJECTIVES: Optimal management if male breast cancer (MBC) is not clearly established and treatment guidelines are scarce.
  • We evaluated our own results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognostic factors for survival.
  • PATIENTS AND METHODS: Thirty-nine patients with MBC were retrospectively studied to evaluate the results in this type of tumor; 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobuler carcinoma (ILC).
  • The distribution according to stage was 12.8%, 46.2%, 30.7% and 10.3% in Stages I, II, III and IV, respectively; 7.7% underwent radiotherapy (RT)+/-hormonotherapy (HT), 22.8% had chemotherapy (CT), 61.8% had chemoradiotherapy (CRT)+/-HT and 7.7% had HT in addition to surgery.
  • In a univariate analysis for OS, statistical significance was found for lymph node metastases (P=.00001), stage (P=.0098) and age (P=.03), while presence of RT in the treatment modality (P=.6849), and tumor size (P=.4439) demonstrated no significance.
  • [MeSH-major] Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy. Carcinoma / mortality. Carcinoma / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Male. Mastectomy. Middle Aged. Neoplasm Staging. Radiotherapy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063538.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Tsunoda-Shimizu H, Hayashi N, Hamaoka T, Kawasaki T, Tsugawa K, Yagata H, Kikuchi M, Suzuki K, Nakamura S: Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging. Breast Cancer; 2008;15(2):133-40
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
  • BACKGROUND: Neoadjuvant chemotherapy has recently become common therapy for breast cancer.
  • This work studied whether or not the effects of neoadjuvant chemotherapy can be predicted from morphological features of breast cancer in initial diagnostic imaging.
  • MATERIALS AND METHODS: A total of 186 cases who underwent neoadjuvant chemotherapy at this hospital in 2006 were studied.
  • One is a type of invasive carcinoma that tends to grow along the mammary ducts (type A1), another is a type of expansively growing invasive carcinoma that is relatively well-defined (type A2), a third is a type of irregularly shaped mass that retracts surrounding tissue (type A3), and the fourth is a mixed type.
  • Thus, the effects of neoadjuvant chemotherapy on carcinomas of the four types were compared on the basis of image and pathological findings.
  • Effects of neoadjuvant chemotherapy were classified into three categories of enlarged mass, pCR, and other, with the latter indicating no change or shrinkage.
  • RESULTS: Of the 186 total cases, 72 were classified as type A1, 31 as type A2, 52 as type A3, and 31 as a mixed type.
  • Seven of 31 cases of type A2 (22.6%) were cases of an enlarged mass, revealing a high percentage of such cases.
  • Dividing cases into type A2 and other types and looking at the proportion of cases of an enlarged mass thus indicated a significantly higher tendency. pCR was achieved in 6 of 31 cases with type A2 (19.4%).
  • Here, also, the proportion of type A2 cases was significantly higher.
  • CONCLUSION: Morphological features prior to neoadjuvant chemotherapy can contribute to determining the effects of the therapy.
  • Expansively growing well-defined masses contain lesions at both extremes, tending to enlarge in some instances or instead allowing pCR, so the course of therapy must be carefully followed when performing neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Neoadjuvant Therapy
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Ductal, Breast / classification. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Diagnostic Imaging. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Middle Aged. Prognosis. Retrospective Studies. Stereoisomerism. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288570.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


9. Mirza IA, Shahab N: Small cell carcinoma of the breast. Semin Oncol; 2007 Feb;34(1):64-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the breast.
  • Small cell carcinoma of the breast (SCCB) is an uncommon neoplasm that accounts for less than 1% of primary breast cancers.
  • Histologically, these tumors have striking similarities to small call carcinoma of the lung, usually with evidence of associated ductal carcinoma-in-situ (DCIS) with areas of ductal, lobular, or papillary differentiation.
  • Treatment, which may include surgery, radiotherapy, and combination chemotherapy, is based on clinical stage and the presence of metastases.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Small Cell

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270668.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Number-of-references] 34
  •  go-up   go-down


10. Kubota K, Ogawa Y, Nishioka A, Murata Y, Itoh S, Hamada N, Morio K, Maeda H, Tanaka Y: Radiological imaging features of invasive micropapillary carcinoma of the breast and axillary lymph nodes. Oncol Rep; 2008 Nov;20(5):1143-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological imaging features of invasive micropapillary carcinoma of the breast and axillary lymph nodes.
  • Invasive micropapillary carcinoma of the breast is of growing clinical significance.
  • The purpose of this study was to identify the radiological imaging features for this type of breast carcinoma and the axillary lymph nodes.
  • The study population consisted of 30 breast cancer patients (8 invasive micropapillary carcinomas and 22 other types of invasive ductal carcinoma).
  • The breast lesions were evaluated with mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (MRI) prior to neoadjuvant chemotherapy.
  • Only contrast-enhanced MRI showed characteristic findings for invasive micropapillary carcinoma.
  • Although invasive micropapillary carcinoma is commonly irregular in shape (7/8) compared with other types of invasive carcinoma (6/22) (p=0.012, chi(2) test), a careful interpretation of radiological imaging to identify lesion borders helped the complete clearance of cancer cells from 6/8 patients with invasive micropapillary carcinoma in one-time breast conservative surgery.
  • The positive and negative predictive values of sonography in diagnosing axillary lymph node metastases in cases of invasive micropapillary carcinoma were 100 and 50%, respectively.
  • In conclusion, contrast-enhanced MRI reveals the irregular shape of invasive micropapillary carcinoma and helps conservative breast surgery to be performed safely.
  • The pathological analysis of axillary nodes in cases of invasive micropapillary carcinoma may prove to be indispensable due to the relatively low negative predictive value of sonography.
  • [MeSH-major] Breast Neoplasms / radiography. Carcinoma, Papillary / radiography. Lymphatic Metastasis / radiography. Magnetic Resonance Imaging. Mammography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949414.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Chen L, Fan Y, Lang RG, Guo XJ, Sun YL, Fu L: [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. Zhonghua Bing Li Xue Za Zhi; 2007 Apr;36(4):228-32
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and prognosis study of breast carcinoma with micropapillary component].
  • OBJECTIVE: To study the diagnostic criteria, clinicopathologic characteristics and prognosis of invasive micropapillary carcinoma (IMPC) of breast.
  • METHODS: All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed.
  • One hundred examples with IMPC component, according to the 2003 World Health Organization classification of breast tumors, were identified.
  • Univariate and multivariate analysis showed that the prognosis of patients was adversely affected by the presence of lymphovascular invasion and family history of breast cancer.
  • On the other hand, tamoxifen therapy and adjuvant chemotherapy improved survival.
  • CONCLUSIONS: Breast carcinoma with IMPC component is associated with poor prognosis, despites the relative proportion of this architectural pattern.
  • The overall prognosis is related to the presence of lymphovascular invasion and family history of breast cancer.
  • Hormonal therapy and individualized chemotherapy can improve the survival rate.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Papillary / diagnosis. Mastectomy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706112.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


12. Enomoto K, Sakurai K, Amano S, Shiono M: [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2490-2
MedlinePlus Health Information. consumer health - Hyperthyroidism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism].
  • Around the year 2006, the right breast lump was found by palpating.
  • A medical check-up was done and diagnosed as T4b, N0, M0, stage IIIB of the breast cancer by a close inspection.
  • In January 2009, we observed a bleeding from the part of the breast cancer.
  • Then we performed a pectoralis muscle preservation breast surgery and dermanaplasty with a shortest anesthesia time in order to control the infestation to be minimal.
  • Because we were able to control the hyperthyroidism this time and a thyroid function to be stabilized for a local advanced breast carcinoma with the hemorrhage temporarily, and were able to operate for the breast cancer, as we reported it in this study.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Hemorrhage / etiology. Hyperthyroidism / drug therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / surgery. Carcinoma, Papillary / complications. Carcinoma, Papillary / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037465.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Yoney A, Kucuk A, Unsal M: Male breast cancer: a retrospective analysis. Cancer Radiother; 2009 Apr;13(2):103-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer: a retrospective analysis.
  • BACKGROUND: To evaluate our results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognosis factors for survival.
  • PATIENTS AND METHODS: Thirty-nine patients with male breast cancer have been retrospectively studied with the trial aim to evaluate the results of our practice.
  • Among them, 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobular carcinoma (ILC) and the distribution according to stage was found to be 12.8, 46.2, 30.7 and 10.3% in Stages I, II, III and IV, respectively.
  • Among the patients, 7.7% received radiotherapy (RT) and hormonotherapy (HT), 22.8% received chemotherapy (CT), 61.8% received chemoradiotherapy (CRT) and HT and 7.7% received HT in addition to surgery.
  • In our series, univariate analysis for OS demonstrated statistical significance for lymph node metastases (p=0.00001), stage (p=0.0098) and age (p=0.03); while RT in the treatment modality (p=0.6849), and tumor size (p=0.4439) demonstrated no significance.
  • CONCLUSION: Postoperative radiotherapy was important in the management of male breast cancer to improve LC resulting in one local failure, but did not improve OS and DFS in our analysis.
  • [MeSH-major] Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / therapy. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250851.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG: Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol; 2003 Apr;7(2):112-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
  • Carcinomas with micropapillary features have been described in the breast, urinary bladder, lung, and ovary.
  • The metastatic carcinoma can consist exclusively of the micropapillary component, which may elicit an erroneous diagnosis if located in the bladder or lung, as in the patient presented herein.
  • We present a case of a 59-year-old woman with a history of bilateral breast carcinoma status post-bilateral mastectomy, chemotherapy, and tamoxifen therapy.
  • A biopsy of the endometrium revealed a poorly differentiated carcinoma.
  • Urinary bladder biopsies showed a carcinoma with micropapillary features diagnosed as micropapillary transitional cell carcinoma.
  • Anderson Cancer Center (Houston, TX) for further treatment recommendations.
  • The mastectomy specimen showed an invasive ductal carcinoma with a significant micropapillary component.
  • The tumor cells from the breast, endometrium, and urinary bladder were positive for cytokeratin (CK) 7 and estrogen receptor and negative for CK20.
  • In view of the morphologic and immunohistochemical profile, the carcinoma in the endometrium and urinary bladder were interpreted as metastatic lesions from the breast primary.
  • Carcinomas with a micropapillary component are morphologically identical in the breast, urinary bladder, and lung.
  • However, micropapillary serous carcinoma has a different appearance more akin to borderline tumors of the ovary.
  • Immunohistochemical stains are useful in distinguishing these lesions in that thyroid transcription factor-1 positivity suggests a lung primary, CK7 and estrogen receptor suggest a breast primary, and both CK7 and CK20 positivity suggest a urinary bladder primary.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Papillary / secondary. Endometrial Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / metabolism. Lung Neoplasms / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12715337.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


15. Xue Y, Guo XT, Liu WC: [Clinical research advancement on male breast cancer]. Ai Zheng; 2007 Oct;26(10):1148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research advancement on male breast cancer].
  • Male breast cancer is a rare disease and the incidence has increased over the past 25 years.
  • Current knowledge regarding its biology, natural history, and treatment strategies is mainly based on the research findings on female breast cancer.
  • Hormonal imbalances, such as gonadal dysfunction, obesity, and radiation exposure also contribute to the occurrence of male breast cancer.
  • Most cases are ductal tumors and 10% of the cases are ductal carcinoma in situ.
  • Indications for radiotherapy, as well as the steps and methods, are similar to that for female breast cancer.
  • Because 90% of the patients are estrogen receptor-positive, tamoxifen is a standard adjuvant therapy, but some individuals could also benefit from chemotherapy.
  • In this article, the latest information on the epidemiology, biology, and treatment of male breast cancer is reviewed.
  • [MeSH-major] Breast Neoplasms, Male / therapy. Carcinoma, Ductal, Breast / therapy. Mastectomy / methods. Tamoxifen / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis Regulatory Proteins. BRCA2 Protein / genetics. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Humans. Male. Methotrexate / therapeutic use. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927890.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 094ZI81Y45 / Tamoxifen; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF protocol
  • [Number-of-references] 47
  •  go-up   go-down


16. Ohri A, Jetly D, Shukla K, Bansal R: Cytological grading of breast neoplasia and its correlation with histological grading. Indian J Pathol Microbiol; 2006 Apr;49(2):208-13
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological grading of breast neoplasia and its correlation with histological grading.
  • Cytological grading of breast cancer is not well established despite histological grading having gained a strong foothold.
  • In our study we have analyzed 50 cases of breast carcinoma which included invasive ductal carcinoma, invasive lobular carcinoma, mucinous carcinoma, stromal sarcoma, apocrine carcinoma, papillary carcinoma.
  • Simplified Black grading system has been recommended for cytological grading of breast neoplasia because of its lucidity and its reproducibility.
  • Cytological grading of breast neoplasia is important for neo adjuvant chemotherapy and also for predicting the prognosis of the patient on FNAC alone.
  • [MeSH-major] Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933716.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  •  go-up   go-down


17. Leboeuf R, Bénard F, Langlois MF: Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid. Clin Nucl Med; 2006 Jul;31(7):382-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
  • Furthermore, a relationship between breast and thyroid carcinoma has been previously proposed.
  • CASE DESCRIPTION: We describe the case of a 59-year-old woman who presented with simultaneous papillary and breast carcinoma within the thyroid gland.
  • F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) done for the evaluation of her metastatic breast cancer revealed a thyroid incidentaloma with a high metabolic rate (standardized uptake value [SUV] of 13).
  • She underwent thyroidectomy and the pathology revealed papillary thyroid carcinoma corresponding to the lesion visualized on FDG PET.
  • However, small metastatic implants of breast carcinoma were seen within the opposite thyroid lobe.
  • CONCLUSION: This is a rare description of a concomitant papillary thyroid carcinoma presenting as an FDG PET incidentaloma alongside breast cancer metastases to the thyroid gland.
  • Thyroid and breast cancer sometimes occur in the same patient.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Papillary / radionuclide imaging. Estrogens. Incidental Findings. Neoplasms, Hormone-Dependent / radionuclide imaging. Neoplasms, Hormone-Dependent / secondary. Neoplasms, Second Primary / radionuclide imaging. Positron-Emission Tomography. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Mastectomy, Segmental. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Middle Aged. Neoplasm Proteins / analysis. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / radiography. Neoplasms, Radiation-Induced / radionuclide imaging. Radiopharmaceuticals / therapeutic use. Radiotherapy, Adjuvant. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tamoxifen / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785803.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Iodine Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol; 2008 Apr;129(4):563-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
  • We performed a technical and cost-effectiveness analysis of quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) for the assessment of HER2 in breast cancer.
  • We evaluated 44 frozen and 55 formalin-fixed paraffin-embedded (FFPE) breast carcinoma specimens by Q-RT-PCR, immunohistochemical analysis, and fluorescent in situ hybridization (FISH).
  • Immunohistochemical and FISH analyses were performed on individual slides and on tissue microarray.
  • Cost analysis documented the advantage of Q-RT-PCR in all US Food and Drug Administration-approved assays.
  • Our data support the use of Q-RT-PCR for testing breast cancer specimens to select patients for HER2 inhibitory therapy.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction / economics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apocrine Glands / metabolism. Apocrine Glands / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cost-Benefit Analysis. Female. Gene Expression. Humans. In Situ Hybridization, Fluorescence / economics. In Situ Hybridization, Fluorescence / methods. Middle Aged. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / metabolism. Sweat Gland Neoplasms / pathology. Tissue Array Analysis / economics. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343783.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


19. Shigematsu H, Nakamura Y, Tanaka K, Shiotani S, Koga C, Kawaguchi H, Nishimura S, Taguchi K, Nishiyama K, Ohno S: A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. Int J Clin Oncol; 2010 Dec;15(6):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
  • We report a case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a complete response to trastuzumab and paclitaxel treatment.
  • A 37-year-old woman was referred to our hospital for right breast swelling with broad skin redness and right axillary tumor.
  • The histopathological findings of core-needle biopsy specimens from primary breast tumor and ipsilateral axillary lymph node were invasive ductal carcinoma with a micropapillary component.
  • Advanced inflammatory breast cancer with an invasive micropapillary component was diagnosed (T4d N3 M1 (LYM), stage IV).
  • The patient was treated with combination chemotherapy using weekly paclitaxel and trastuzumab.
  • After administration of three courses, the breast swelling, skin redness, and lymph node swelling disappeared completely.
  • Invasive micropapillary carcinoma is known to be an aggressive histological type associated with a high incidence of lymph node metastasis and poor prognosis.
  • This is the first reported case of advanced inflammatory breast cancer with an invasive micropapillary component showing a clinically complete response to trastuzumab-containing treatment.
  • This report suggests trastuzumab-containing chemotherapy is a promising therapy for HER-2-positive advanced invasive micropapillary carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Papillary / drug therapy. Inflammatory Breast Neoplasms / drug therapy. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Female. Humans. Lymphatic Metastasis. Paclitaxel / administration & dosage. Trastuzumab. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2009 Jun;13(3):151-7 [19433292.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Jan;34(1):65-8 [17220672.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Histopathology. 2004 Apr;44(4):332-8 [15049898.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4247-50 [15911863.001]
  • [Cites] Pathol Res Pract. 1994 Aug;190(7):668-74 [7808965.001]
  • [Cites] Histopathology. 2004 Jan;44(1):18-23 [14717664.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):740-6 [17050071.001]
  • [Cites] Clin Transl Oncol. 2006 Oct;8(10 ):761-3 [17074677.001]
  • [Cites] N Engl J Med. 1998 Oct 1;339(14):974-84 [9753714.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):90-6 [14720138.001]
  • [Cites] Arch Pathol Lab Med. 2005 Oct;129(10):1277-82 [16196516.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1459-63 [10667424.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):857-66 [15198358.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5117-25 [15955906.001]
  • [Cites] Int J Surg Pathol. 2008 Apr;16(2):155-63 [18417672.001]
  • (PMID = 20473628.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


20. Vrdoljak E, Mise BP, Lukić B, Curić Z, Bosković L, Tica I: Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. Onkologie; 2010;33(1-2):53-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
  • BACKGROUND: The optimal duration of ixabepilone and capecitabine chemotherapy combination is currently not known and will most likely be patient-specific based on efficacy, toxicity, quality of life, and patient preference.
  • CASE REPORT: We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes.
  • CONCLUSIONS: This report adds to the pool of knowledge regarding the use of this important new metastatic breast cancer regimen, especially with respect to the optimal duration of its use.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal / secondary. Carcinoma, Papillary / secondary. Lung Neoplasms / secondary. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Biomarkers, Tumor / genetics. Capecitabine. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Epothilones / administration & dosage. Epothilones / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Long-Term Care. Middle Aged. Randomized Controlled Trials as Topic. Receptor, ErbB-2 / genetics. Receptors, Estrogen / genetics. Receptors, Progesterone / genetics


21. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


22. Nio Y, Toga T, Maruyama R, Fukushima M: Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy. Oncol Rep; 2007 Jul;18(1):59-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
  • The enzyme orotate phosphoribosyl transferase (OPRT) is involved in the metabolism of the anticancer drug 5-fluorouracil (5-FU), and is a key enzyme for conversion of 5-FU to its active form in tumor tissue.
  • The present study was designed to assess the association between the activity of OPRT in the tumor, and the clinicopathological status and prognosis of human resectable pancreatic cancer, especially regarding its relevance to the efficacy of adjuvant chemotherapy with uracil and tegafur (UFT), cyclophosphamide (CPA) and/or gemcitabine (GEM).
  • The present study included 99 resectable pancreatic cancers, which were all invasive ductal tubular carcinomas.
  • In the OPRT (+) group, the survival rate of the patients, who received adjuvant chemotherapy (ACT) with UFT, CPA or GEM, was significantly higher than that of the patients without ACT; however, in the OPRT (-) group, there was no difference in the survival between the ACT (+) and (-) groups.
  • The present study is the first report on the significance of OPRT in human pancreatic cancer, and the results indicate that the expression of OPRT may be useful to predict the response to adjuvant chemotherapy in human pancreatic cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / enzymology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Papillary / enzymology. Orotate Phosphoribosyltransferase / metabolism. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549346.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • Preoperative diagnosis of fallopian tube carcinoma is difficult due to the rarity and silent course of this neoplasm.
  • We present herein the case of a 58-year-old woman with primary fallopian tube carcinoma that was diagnosed preoperatively on the basis of a positive for adenocarcinoma Papanicolaou vaginal smear, repeated episodes of vaginal bleeding, negative endocervical and endometrial curettage, characteristic features on ultrasonography and elevated CA-125 levels.
  • Pathologic confirmation of primary serous papillary adenocarcinoma of the left fallopian tube was made.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


24. Horii R, Akiyama F: [Histological features of breast cancer as predictive factors for chemotherapy]. Nihon Rinsho; 2007 Jun 28;65 Suppl 6:160-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological features of breast cancer as predictive factors for chemotherapy].
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Papillary / pathology. Forecasting

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679197.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 4
  •  go-up   go-down






Advertisement